SCHEMBL1744046

SCHEMBL1744046

O=CNc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
MAP2K1 Q02750 7/20 0.35
MAP2K2 P36507 2/20 0.34
PRKCZ Q05513 1/20 0.34
IARS2 Q9NSE4 1/20 0.34
TYMP P19971 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
CA2 P00918 1/20 0.32
CNR2 P34972 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL1744741 0.97 LMNA (0.51) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL2763330 0.95 LMNA (0.49) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL20034199 0.87 LMNA (0.50) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL19645483 0.85 LMNA (0.45) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL8378687 0.82 LMNA (0.56) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL2784245 0.82 LMNA (0.56) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL12657374 0.82 LMNA (0.56) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL3426791 0.80 LMNA (0.59) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL11292903 0.80 LMNA (0.59) LMNACYP2C19HIF1AEGFRSRC
SCHEMBL619944 0.79 LMNA (0.60) LMNACYP2C19HIF1AEGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2917174-B1 PREPARATION OF INTERMEDIATES OF X-RAY CONTRAST AGENTS GE HEALTHCARE AS (NO) 2018-09-12 EP claimed
US-9403757-B2 Preparation of intermediates of X-ray contrast agents GE HEALTHCARE AS (NO) 2016-08-02 US claimed
US-20150274645-A1 PREPARATION OF INTERMEDIATES OF X-RAY CONTRAST AGENTS GE HEALTHCARE AS (NO) 2015-10-01 US claimed
EP-2900632-B1 PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL GE HEALTHCARE AS (NO) 2019-10-30 EP disclosed
EP-2917174-B1 PREPARATION OF INTERMEDIATES OF X-RAY CONTRAST AGENTS GE HEALTHCARE AS (NO) 2018-09-12 EP disclosed
US-9938233-B2 Purification of X-ray contrast agents GE HEALTHCARE AS (NO) 2018-04-10 US disclosed
US-9884808-B2 Preparation of an intermediate compound of ioforminol GE HEALTHCARE AS (NO) 2018-02-06 US disclosed
US-9827334-B2 Preparation of ioforminol, an x-ray contrast agent GE HEALTHCARE AS (NO) 2017-11-28 US disclosed
US-9738596-B2 Contrast agents GE HEALTHCARE AS (NO) 2017-08-22 US disclosed
US-20160304440-A1 PURIFICATION OF X-RAY CONTRAST AGENTS GE HEALTHCARE AS (NO) 2016-10-20 US disclosed
US-9403757-B2 Preparation of intermediates of X-ray contrast agents GE HEALTHCARE AS (NO) 2016-08-02 US disclosed
US-20110256068-A1 CONTRAST MEDIA COMPOSITIONS GE HEALTHCARE AS (NO) 2011-10-20 US disclosed
US-D647037-S1 Tire tread LO TSAI JEN 2011-10-18 US disclosed
US-20100322868-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-12-23 US disclosed
WO-2010079201-A1 CONTRAST MEDIA COMPOSITIONS GE HEALTHCARE AS (NO) 2010-07-15 WO disclosed
EP-2178568-A2 CONTRAST AGENTS GE Healthcare AS (NO) 2010-04-28 EP disclosed
WO-2009008734-A2 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2009-01-15 WO disclosed
EP-0855997-A4 FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA BIOPHYSICA INC (US) 1998-10-07 EP disclosed
EP-0855997-A1 FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA BIOPHYSICA, INC. (US) 1998-08-05 EP disclosed
WO-1997000240-A1 FORMYL DERIVATIVES AS NONIONIC CONTRAST MEDIA BIOPHYSICA FOUNDATION (US) 1997-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304440-A1 PURIFICATION OF X-RAY CONTRAST AGENTS TMEM97, OGFR, TMEM120A LMNA 721/4885CYP2C19 3870/4885HIF1A 1865/4885
US-20150274645-A1 PREPARATION OF INTERMEDIATES OF X-RAY CONTRAST AGENTS NAF1, NAA15, NAAA LMNA 486/4885CYP2C19 2574/4885HIF1A 876/4885
US-20110256068-A1 CONTRAST MEDIA COMPOSITIONS FPR1, FPR3, TPO LMNA 2641/4885CYP2C19 4295/4885HIF1A 1948/4885
US-20100322868-A1 CONTRAST AGENTS SSTR3, INSR, INSRR LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.